Medicna Interna
Páginas: 2 (265 palabras)
Publicado: 15 de mayo de 2012
n ew england
journal of m edicine
The
established in 1812
march 24, 2011
vol. 364
no. 12
Tiotropium versus Salmeterol for the Prevention
ofExacerbations of COPD
Claus Vogelmeier, M.D., Bettina Hederer, M.D., Thomas Glaab, M.D., Hendrik Schmidt, Ph.D.,
Maureen P.M.H. Rutten-van Mölken, Ph.D., Kai M.Beeh, M.D., Klaus F. Rabe, M.D., and Leonardo M. Fabbri, M.D.,
for the POET-COPD Investigators*
A BS T R AC T
BACKGROUND
Treatment guidelines recommend the useof inhaled long-acting bronchodilators to
alleviate symptoms and reduce the risk of exacerbations in patients with moderate-tovery-severe chronic obstructivepulmonary disease (COPD) but do not specify whether
a long-acting anticholinergic drug or a β2-agonist is the preferred agent. We investigated whether theanticholinergic drug tiotropium is superior to the β2-agonist
salmeterol in preventing exacerbations of COPD.
METHODS
In a 1-year, randomized, double-blind,double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg
of salmeterol twice daily on the incidence ofmoderate or severe exacerbations in
patients with moderate-to-very-severe COPD and a history of exacerbations in the
preceding year.
RESULTS
A total of 7376patients were randomly assigned to and treated with tiotropium
(3707 patients) or salmeterol (3669 patients). Tiotropium, as compared with salmeterol, increasedthe time to the first exacerbation (187 days vs. 145 days), with a 17%
reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90;
P
journal of m edicine
The
established in 1812
march 24, 2011
vol. 364
no. 12
Tiotropium versus Salmeterol for the Prevention
ofExacerbations of COPD
Claus Vogelmeier, M.D., Bettina Hederer, M.D., Thomas Glaab, M.D., Hendrik Schmidt, Ph.D.,
Maureen P.M.H. Rutten-van Mölken, Ph.D., Kai M.Beeh, M.D., Klaus F. Rabe, M.D., and Leonardo M. Fabbri, M.D.,
for the POET-COPD Investigators*
A BS T R AC T
BACKGROUND
Treatment guidelines recommend the useof inhaled long-acting bronchodilators to
alleviate symptoms and reduce the risk of exacerbations in patients with moderate-tovery-severe chronic obstructivepulmonary disease (COPD) but do not specify whether
a long-acting anticholinergic drug or a β2-agonist is the preferred agent. We investigated whether theanticholinergic drug tiotropium is superior to the β2-agonist
salmeterol in preventing exacerbations of COPD.
METHODS
In a 1-year, randomized, double-blind,double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg
of salmeterol twice daily on the incidence ofmoderate or severe exacerbations in
patients with moderate-to-very-severe COPD and a history of exacerbations in the
preceding year.
RESULTS
A total of 7376patients were randomly assigned to and treated with tiotropium
(3707 patients) or salmeterol (3669 patients). Tiotropium, as compared with salmeterol, increasedthe time to the first exacerbation (187 days vs. 145 days), with a 17%
reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90;
P
Leer documento completo
Regístrate para leer el documento completo.